



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ITW

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/ 724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1618
Examiner Name	Jagadishwar Samala
Total Number of Pages in This Submission	6
Attorney Docket Number	330687

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 2 Foreign patent references and 27 non-patent literature documents Information Disclosure Statement (2 pages)
--	--	---

### Remarks

The Director is hereby authorized to charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17; credit any overpayments to the Deposit Account No. 06-0029.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	FAEGRE & BENSON LLP		
Signature			
Printed Name	Richard A. Nakashima		
Date	10/5/06	Reg. No.	42,023

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Laura S. Mellblom	Date	10-5-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No.: 77957-330687

In re Application of:	) Examiner:	Jagadishwar Samala
Goldenberg	)	
	) Art Unit:	1618
	)	
Serial No.: 10/724,397	) Confirmation No.:	8892
	)	
Filed: 12/1/2003	)	
	)	
For: Alpha or Beta Emitters	)	
Attached to Fragments in	)	
Radioimmunotherapy	)	

MAILSTOP: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.97(B)(3) AND 1.98**

Dear Sir:

The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08a-b during examination of the above-identified patent application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 C.F.R. § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality. In accordance with 37 C.F.R. § 1.98(a)(2)(i), copies of the U.S. references are not provided herewith.

**CHARGE OUR DEPOSIT ACCOUNT**


Should any additional fees or any underpayment of fee(s) under 37 CFR 1.16 and 1.17; credit any overpayments be deemed necessary, such fees may be charged to Deposit Account No. 06-0029.

Atty. Docket No.: 77957-330687  
Serial No.: 10/724,397

Respectfully submitted,

FAEGRE & BENSON LLP

Date: October 5, 2006



---

Richard A. Nakashima  
Registration No. 42,023  
Attorney for Applicant

CUSTOMER NO. 35657  
FAEGRE & BENSON LLP  
Tel: (303) 447-7728



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	3	CASEY, J. L., et al., "Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle" British Journal of Cancer (1998) 78(10), 1307-1312 XP-000986994	
	4	ROWLINSON-BUSZA, Gail, et al., "90Y-Labeled Antibody Uptake by Human Tumor Xenografts and The Effect of Systemic Administration of EDTA" Int. J. Radiation Oncology Biol. Phys., Vol. 28, No. 5, pp. 1257-1265, 1994	
	5	DENARDO, Sally J., et al., "Yttrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, Dosimetry and Initial Results in Patients with Incurable Breast Cancer" Anticancer Research 17: 1735-1744 (1997)	
	6	ADAMS, G. P., et al., "Delivery of the a-Emitting Radioisotope Bismuth-213 to Solid tumors via Single-Chain Fv and Diabody Molecules" Nuclear Medicine & Biology, Vol. 27, pp. 339-346, 2000	
	7	BEHR, THOMAS M., et al., "High-Linear Energy Transfer (LET) a versus Low-LET B Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model" Cancer Research 59, 2635-2643, June 1, 1999	
	8	GOVINDAN, SERENGULAM V., et al., "90 Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies" Bioconjugate Chem. 1998, 9, 773-782	
	9	WONG, JEFFREY Y. C., et al., "A Phase I Radioimmunotherapy Trial Evaluating 90 Yttrium-labeled Anti-Carcinoembryonic antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies" Clinical Cancer Research, Vol. 6, 3855-3863, October 2000	
	10	DAVIS, ILA A. et al., "Radioimmunotherapy Using Vascular Targeted 213Bi: The Role of Tumor Necrosis Factor a in the Development of Pulmonary Fibrosis" Clinical Cancer Research: 3160s Vol. 5, 3160s-3164s, October 1999 (Suppl.)	
	11	WATANABE, NAOYUKI, et al., "CaNa2 EDTA for Improvement of Radioimmunodetection and Radioimmunotherapy with 111In and 90Y-DTPA-Anti-CEA MABs in Nude Mice Bearing Human Colorectal Cancer" The Journal of Nuclear Medicine, Vol. 41, No. 2, February 2000, pgs 338-344	
	12	JONES, SHAUN B. et al. "Evaluation of Dithiol Chelating Agents as Potential Adjuvants for Anti-IL-2 Receptor Lead or Bismuth Alpha Radioimmunotherapy" Nuclear Medicine & Biology, Vol. 23, pp. 105-113, 1996	
	13	GOODWIN, D. A., et al., "Monoclonal antibody hapten radiopharmaceutical delivery" Nuclear Medicine Communications 7, 569-580 (1986)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 4

**Complete if Known**

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	JUWEID, MALIK E., et al., "Phase I/II Trial of 131I-MN-14 F(ab)2 Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma" Cancer April 15, 1999, Vol. 85, No. 8, pg. 1828-1842	
	15	KARACAY, et al., "Development of a Streptavidin--Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Reagent Development" Bioconjugate Chem. 1997, 8, 585-594	
	16	BEHR, THOMAS M., et al., "Phase I/II Clinical Radioimmunotherapy with an Iodine-131-Labeled Anti-Carcinoembryonic antigen Murine Monoclonal Antibody IgG" The Journal of Nuclear Medicine, Vol. 38, No. 6, June 1997, pgs. 858-870	
	17	ULLEN, ANDERS, et al. "Use of Anticytokeratin Monoclonal Anti-Idiotypic Antibodies to Improve Tumor: Nontumor Ratio in Experimental Radioimmunolocalization" Cancer Research (Suppl.) 55, 5868s-5873s, December 1, 1995	
	18	ONG, GAIK LIN, et al. "The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotypic antibodies" Cancer Immunol Immunotherapy (1994) 39: 325-331	
	19	SHARKEY, ROBERT M., et al., "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14" Cancer March 15, 1993, Vol. 71, No. 6 pgs. 2082-2846	
	20	PIMM, M. V., et al. "Influence of syngeneic monoclonal anti-idiotypic antibodies to murine Monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments" J Cancer Res Clinical Oncology (1993) 119:408-414 pgs 408-414	
	21	SCHIELE, J., et al., "The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotypic mAb in murine B cell lymphoma" Radiotherapy and Oncology, 24 (1992) 169-176 pgs. 169-176	
	22	SHARKEY, ROBERT M., et al., "Enhanced Clearance of Radiolabeled Murine Monoclonal Antibody by a Syngeneic Anti-Idiotypic Antibody in Tumor-Bearing Nude Mice" Int. J. Cancer 51, 266-273 (1992)	
	23	GOLDENBERG, DAVID M., et al., "Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody" Journal of Clinical Oncology, Vol. 9, No. 4 (April 1991), pp. 548-564	
	24	STEWART, J. SIMON W., et al., "Clearance of 131I-labeled Murine Monoclonal Antibody from Patients' Blood by Intravenous Human Anti-Murine Immunoglobulin Antibody" Cancer Research 50, 563-567, February 1, 1990	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	25	BLUMENTHAL, RASALYN D. et al., "Reduction by Anti-Antibody Administration of the Radiotoxicity Associated with 131I-Labeled Antibody to Carcinoembryonic Antigen in Cancer Radioimmunotherapy" Journal of the National Cancer Institute Vol. 81, No. 3, February 1, 1989	
	26	PIMM, M. V., et al., "The Influence of Syngeneic Anti-Idiotypic Antibody on the Biodistribution of an anti-tumour monoclonal Antibody in Balb/c Mice" Int. J. Cancer: 43, 147-151 (1989)	
	27	SHARKEY, ROBERT M., et al., "Factors Influencing Anti-Antibody Enhancement of Tumor Targeting with Antibodies in Hamsters with Human Colonic Tumor Xenografts" Cancer Research 48, 2005-2009, April 15, 1988	
	28	GOLDENBERG, DAVID M., et al., "Anti-Antibody Enhancement of Iodine-131 Anti-CEA Radioimmunodetection in Experimental and Clinical Studies" The Journal of Nuclear Medicine, Volume 28, Number 10, October 1987, pp 1604-1610	
	29	SHARKEY, Robert M., et al. "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14" Cancer March 15, 1993, Volmue 71, No. 6, pp 2082-2096	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.